| Topic | Key points | Quantitative data | Key sources (short cite with year and DOI/URL) |
|---|---|---|---|
| Definition & inheritance | Primary coenzyme Q10 deficiency (PCoQD) is a group of mitochondrial respiratory-chain disorders caused by reduced tissue/cellular CoQ10 associated with **biallelic** pathogenic variants in CoQ biosynthesis genes; reported inheritance is predominantly **autosomal recessive**. It is potentially treatable, especially if recognized before irreversible organ injury. (pqac-00000009, pqac-00000010, pqac-00000006) | GeneReviews overview refers to **10 genes**; review literature notes **~300 patients identified** and ~**100 treated** with CoQ10. (pqac-00000009, pqac-00000003) | Salviati et al. 2023, GeneReviews overview; Mantle et al. 2023, DOI: https://doi.org/10.3390/antiox12081652; Mantle & Hargreaves 2024, DOI: https://doi.org/10.3390/antiox13050530 |
| Causal genes | Core disease genes supported across recent reviews/cohorts: **PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7, COQ8A, COQ8B, COQ9**; neuroimaging review also includes **HPDL** among primary CoQ10-biosynthesis disorders discussed. (pqac-00000009, pqac-00000019, pqac-00000001) | **10** canonical CoQ biosynthesis genes in GeneReviews; **11 disease genes** in Münch et al. when HPDL is included. (pqac-00000009, pqac-00000019) | Salviati et al. 2023, GeneReviews overview; Münch et al. 2023, DOI: https://doi.org/10.3390/antiox12030718; Wahedi et al. 2024, DOI: https://doi.org/10.1212/nxg.0000000000200209 |
| Core phenotypes | Multisystem but classically neurologic and renal. Neurologic features include **encephalopathy, developmental delay/regression, ataxia/cerebellar atrophy, seizures/epilepsy, movement disorder, hypotonia, intellectual disability**. Renal disease includes **steroid-resistant nephrotic syndrome (SRNS)** and progression to ESKD. Cardiac disease includes **cardiomyopathy**. Ocular/auditory involvement includes **optic atrophy, retinopathy**, and in some gene-specific forms hearing loss. (pqac-00000010, pqac-00000014, pqac-00000019, pqac-00000011) | In one 14-patient cohort: **seizures 8/14**; **lactate elevated 5/12 tested**; **SRNS 3/14**. COQ8A neuroimaging review reports cerebellar atrophy in **94%** of patients described. Hyperlactatemia in neonatal COQ4 review: **18/24 (75%)**. (pqac-00000000, pqac-00000015) | Wahedi et al. 2024, DOI: https://doi.org/10.1212/nxg.0000000000200209; Münch et al. 2023, DOI: https://doi.org/10.3390/antiox12030718; Pan et al. 2024, DOI: https://doi.org/10.3389/fped.2024.1410133 |
| Diagnostics | Biochemical diagnosis favors **skeletal muscle biopsy** and/or **skin fibroblasts**; plasma CoQ10 may be normal and is not reliable diagnostically. Assays include **HPLC-UV / HPLC-electrochemical detection** for CoQ10 and respiratory-chain functional testing showing reduced **complex I+III and II+III** activities. Less invasive approaches include **PBMNC CoQ10** and urinary CoQ10 in some contexts. Molecular diagnosis uses **multigene panels, WES/WGS**, with genome-wide testing recommended because no pathognomonic blood, muscle, or imaging biomarkers exist. (pqac-00000011, pqac-00000007, pqac-00000002, pqac-00000001) | Cohort evidence: **20/24** neonatal COQ4 cases diagnosed by **WES**. (pqac-00000000) | Salviati et al. 2023, GeneReviews overview; Mantle et al. 2023, DOI: https://doi.org/10.3390/antiox12081652; Hargreaves & Mantle 2023, DOI: https://doi.org/10.20944/preprints202305.1024.v1; Wahedi et al. 2024, DOI: https://doi.org/10.1212/nxg.0000000000200209 |
| Treatment & monitoring | Standard disease-directed treatment is **oral CoQ10 supplementation**; recent pediatric review describes common study dosing of **10–30 mg/kg/day**, while the 2024 single-center cohort reports neurologic improvement often required **up to 70 mg/kg/day** and renal benefit at about **30 mg/kg/day**. **Idebenone** was added in some patients at **10–20 mg/kg/day** for seizure control. **PBMNC CoQ10** can monitor treatment absorption/response. (pqac-00000003, pqac-00000001, pqac-00000000) | PBMNC CoQ10 increases reported in individual patients: **+352%**, **+146% then +320%**, **+221%**. In the cohort, **11/14** received CoQ10. (pqac-00000000) | Mantle & Hargreaves 2024, DOI: https://doi.org/10.3390/antiox13050530; Wahedi et al. 2024, DOI: https://doi.org/10.1212/nxg.0000000000200209 |
| Epidemiology & prognosis | PCoQD is very rare. Reviews cite prevalence/incidence estimates **<1 per 100,000 population**; another estimate suggested roughly **120,000 patients worldwide**. Prognosis depends strongly on gene, organ involvement, and timing of treatment: **early renal disease can reverse or be prevented**, whereas **neonatal/infantile neurologic forms often have poor survival despite therapy**. (pqac-00000003, pqac-00000026, pqac-00000010, pqac-00000001) | Neonatal COQ4 literature review: mortality **9/12 (75%)** in Chinese cases vs **11/12 (91.7%)** elsewhere; mean survival **60.0 ± 98.0 days**; only **9/24** received CoQ10 and **all 4 survivors** had CoQ10 supplementation. In Wahedi cohort, **3 children with neonatal-onset neurologic disease died in early childhood despite high-dose CoQ10 from birth**; early treatment reportedly **reversed renal manifestations and prevented kidney disease over 10 years**. (pqac-00000000, pqac-00000001) | Pan et al. 2024, DOI: https://doi.org/10.3389/fped.2024.1410133; Wahedi et al. 2024, DOI: https://doi.org/10.1212/nxg.0000000000200209; Mantle & Hargreaves 2024, DOI: https://doi.org/10.3390/antiox13050530 |


*Table: This table compiles the core disease-defining features, genes, phenotypes, diagnostics, treatments, and recent quantitative outcome data for primary coenzyme Q10 deficiency. It is designed as a compact evidence-backed reference for knowledge-base curation.*